Verastem (VSTM) Cash from Investing Activities (2011 - 2026)
Verastem (VSTM) recorded quarterly Cash from Investing Activities of -$16.0 million in Q1 2026, down 1090.71% quarter-over-quarter from -$1.3 million in Q4 2025.
Verastem (VSTM) Cash from Investing Activities (2011 - 2026) Analysis & Trends
Verastem's Cash from Investing Activities history runs 16 years deep, the most recent figure standing at -$16.0 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities changed N/A year-over-year to -$16.0 million; the TTM figure through Mar 2026 stood at -$17.4 million (changed N/A YoY), while the FY2025 annual figure was -$9.6 million, down 116.05% from the prior year.
- Cash from Investing Activities was -$16.0 million for Q1 2026 at Verastem, down from -$1.3 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $31.0 million in Q1 2024 to a low of -$70.1 million in Q3 2023.
- Historically, Cash from Investing Activities has averaged $5.4 million across 5 years, with a median of $12.7 million in 2022.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities soared 19634.85% in 2022, then slumped 1608.05% in 2023.
- A 5-year view of Cash from Investing Activities shows it stood at $13.0 million in 2022, then slipped by 4.52% to $12.4 million in 2023, then soared by 133.14% to $29.0 million in 2024, then sank by 104.64% to -$1.3 million in 2025, then sank by 1090.71% to -$16.0 million in 2026.
- The last three Cash from Investing Activities figures came in at -$16.0 million (Q1 2026), -$1.3 million (Q4 2025), and $29.0 million (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Verastem | 407.42 Mn | 225.74 Mn | 15.90 Mn | -16.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.02 Mn |
| Mar 31, 2026 | -16.02 Mn |
| Dec 31, 2025 | -1.35 Mn |
| Dec 31, 2025 | -1.35 Mn |
| Jun 30, 2024 | 28.99 Mn |
| Jun 30, 2024 | 28.99 Mn |
| Mar 31, 2024 | 30.98 Mn |
| Mar 31, 2024 | 30.98 Mn |
| Dec 31, 2023 | 12.44 Mn |
| Dec 31, 2023 | 12.44 Mn |
| Sep 30, 2023 | -70.08 Mn |
| Sep 30, 2023 | -70.08 Mn |
| Jun 30, 2023 | 14.00 Mn |
| Jun 30, 2023 | 14.00 Mn |
| Mar 31, 2023 | -804,000.00 |
| Mar 31, 2023 | -804,000.00 |
| Dec 31, 2022 | 13.03 Mn |
| Dec 31, 2022 | 13.03 Mn |
| Sep 30, 2022 | 4.65 Mn |
| Sep 30, 2022 | 4.65 Mn |